Ergocalciferol Dosing for Vitamin D Deficiency
For adults with vitamin D deficiency, treat with ergocalciferol 50,000 IU once weekly for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily. This is the standard evidence-based regimen that effectively corrects deficiency in most patients 1.
Standard Adult Dosing
Loading Phase (Deficiency Correction)
- 50,000 IU once weekly for 8 weeks is the recommended loading regimen 1
- Alternative: 6,000 IU daily for 8 weeks (equivalent total dose) 1
- Target: Achieve 25(OH)D level >30 ng/mL
Maintenance Phase
- 1,500-2,000 IU daily after correction 1
- Alternative: 50,000 IU every 2 weeks has been shown effective in maintaining levels between 35-50 ng/mL 1
Important caveat: Research shows that regimens containing at least 600,000 IU total achieved sufficiency in only 64% of cases 2, and the standard 8-week protocol achieved sufficiency in 56% of patients 3. This means approximately half of patients may need dose adjustment based on follow-up 25(OH)D levels.
Special Populations Requiring Higher Doses
Obesity, Malabsorption, or Drug Interactions
Use 2-3 times the standard dose for patients who are:
- Obese (BMI ≥30 kg/m²)
- Taking anticonvulsants, glucocorticoids, ketoconazole, or AIDS medications
- Have malabsorption syndromes
Specific dosing 1:
- Loading: 6,000-10,000 IU daily (or 100,000-150,000 IU weekly)
- Maintenance: 3,000-6,000 IU daily
Research confirms that BMI ≥30 kg/m² significantly decreases odds of achieving sufficiency with standard dosing 3.
Chronic Kidney Disease (CKD) Patients
For CKD Stage 3-4 with vitamin D deficiency, use double the K/DOQI recommended dose (essentially matching the standard adult deficiency protocol above) 4.
Key CKD considerations:
- Target 25(OH)D >75 nmol/L (>30 ng/mL) 5
- Higher doses (double K/DOQI) significantly increased 25(OH)D from 21 to 33 ng/mL and decreased PTH, while standard K/DOQI dosing only increased 25(OH)D from 21 to 23 ng/mL 4
- Monitor serum calcium and phosphate throughout treatment 1
- Avoid mega-doses ≥100,000 IU and very high 25(OH)D levels >150-200 nmol/L (>60-80 ng/mL) 5
For hemodialysis patients, high-dose ergocalciferol (double K/DOQI) achieved 97% sufficiency versus 76% with conventional dosing, with no increase in adverse events 6.
Pediatric Dosing
Infants (0-1 year)
- Loading: 2,000 IU daily OR 50,000 IU weekly for 6 weeks 1
- Maintenance: 400-1,000 IU daily 1
- Critical warning: Single doses >300,000 IU carry high risk of hypercalcemia in infants 1—avoid bolus dosing
Children (1-18 years)
- Loading: 2,000 IU daily OR 50,000 IU weekly for at least 6 weeks 1
- Maintenance: 600-1,000 IU daily 1
- Children respond similarly to adults when given adult doses 1
Special pediatric considerations
- Children with Williams syndrome or conditions predisposing to hypercalcemia require extreme caution 1
- For CKD children, follow similar principles as adults with appropriate dose adjustments 7
Severe Deficiency Considerations
For severe deficiency (25(OH)D <10-15 ng/mL), consider:
- 50,000 IU three times weekly for 6 weeks (achieved 82% sufficiency) 2
- Alternative for nursing home residents: 50,000 IU three times weekly for 1 month 1
Research demonstrates that 50,000-100,000 IU weekly significantly increases odds of achieving sufficiency (OR 2.61) compared to <50,000 IU weekly 3.
Monitoring and Safety
Follow-up 25(OH)D measurement should occur 8-12 weeks after initiating therapy to assess response 2, 3.
Patients who fail to respond should be evaluated for:
- Non-compliance
- Celiac disease
- Cystic fibrosis
- Severe malabsorption 1
Safety profile: Long-term use of 5,000-50,000 IU daily has been documented as safe without hypercalcemia in hospitalized patients 8. Upper tolerable limits are 10,000 IU daily for adults >8 years, though higher doses may be needed temporarily for deficiency correction 1.
Monitor calcium levels in patients with primary hyperparathyroidism or conditions causing extrarenal 1,25(OH)₂D production, as these patients may develop hypercalcemia when 25(OH)D exceeds 30 ng/mL 1.